Biologics APIs

Dec 08, 2017
By Pharmaceutical Technology Editors
Gilead Sciences will acquire Cell Design Labs to further cell-therapy research and development efforts.
Dec 08, 2017
By Pharmaceutical Technology Editors
The new 30,000-L, $150-million biologics manufacturing facility in Wuxi, China, quintuples the company’s existing manufacturing capability.
Dec 05, 2017
By Pharmaceutical Technology Editors
Biopharma majors are among the industry stakeholders who have commented and raised questions about FDA’s recently proposed draft guidance for analytical assessment of similarity in biosimilars.
Nov 28, 2017
By Pharmaceutical Technology Editors
The acquisition gives GE Healthcare access to a nanofiber-based platform purification technology that can offer improvements in biopharmaceutical productivity.
Nov 20, 2017
By Pharmaceutical Technology Editors
The agency has approved a biologic-based new molecular entity for treating hemophilia A and has expanded the indication for a leukemia drug to now treat a common form of non-Hodgkin lymphoma.
Nov 16, 2017
By Pharmaceutical Technology Editors
As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.
Nov 15, 2017
Pharmaceutical Technology
The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.
Nov 13, 2017
By Pharmaceutical Technology Editors
The companies have established a joint laboratory to develop full continuous processing to manufacture high yields of monoclonal antibodies at reduced costs.
Nov 13, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
Company completes first successful run of what is believed to be the largest synthesis-scale done for oligonucleotide APIs.
Nov 10, 2017
By Pharmaceutical Technology Editors
The company expects to commercially launch the new vaccine in the US in the first quarter of 2018.
native1_300x100
lorem ipsum